Company Update

1Q23 Unaudited Results

PT Kalbe Farma Tbk April 2023

Forward-Looking Statement

This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. ("Kalbe" or the "Company"). This presentation has been prepared solely for use in connection with the release of 31 March 2023 unaudited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation.

The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person. This presentation does not constitute a recommendation regarding the securities of the Company. This presentation, including the information and opinions contained herein, is provided as of the date of this presentation and is subject to change without notice, including change as a result of the issuance of 31 March 2023 unaudited results of the Company.

This presentation includes "forward-looking statements". These statements contain the words "anticipate", "believe", "intend", estimate", "expect" and words of similar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans, objectives relating to the Company's products and services and anticipated product launches) are forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this presentation. The Company expressly disclaims any obligation or reflection of any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any statement is based. Market data and certain industry forecasts used in this presentation were obtained from market research, publicly available information and industry publications which have not been independently verified, and no representation is made as to the accuracy of such information.

Table of Content

Key Updates

Business Overview

Financial Overview

Appendix

4

10

23

29

Key Updates

Growth

Areas

Solid top line growth with sustainable business initiatives

Net Sales

EPS

Growth

Growth

12.2%

3.1%

Innovation for Sustainable Growth

Focus to perform innovation in all line of business:

Prescription Pharma: Specialty category (oncology and biologic)

  • Consumer Health: Preventive category (herbal, vitamin, supplements)
  • Nutritionals: Affordable and Specialty category

Rising Health Awareness

Continuous healthcare information during the pandemic has created a higher demand and consumption of healthy products

Local Content

Innovation to manufacture local products that support government program (JKN) and roadmap through specialty category (oncology and biosimilar), herbal and medical devices (E-care & Elvasense)

Distribution Network & B2B Digital Initiatives

Extensive distribution infrastructure and network to support internal group &

3rd party principal and providing B2B digital platform in healthcare ecosystem (EMOS & MOSTRANS)

International Expansion

Strengthen collaboration with local distribution partners to penetrate the markets and capture demand for Kalbe's products

Collaboration with Strategic Partners

Building closer relationship with global pharmaceutical companies such as Sanofi through acquisition of local entity to enlarge product portfolio

5

Attachments

Disclaimer

PT Kalbe Farma Tbk published this content on 28 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2023 12:32:13 UTC.